S-1 and Bevacizumab in Treating Patients With Colorectal Cancer That is Recurrent or Cannot Be Removed by Surgery

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00974389
Recruitment Status : Unknown
Verified September 2009 by National Cancer Institute (NCI).
Recruitment status was:  Recruiting
First Posted : September 10, 2009
Last Update Posted : August 12, 2013
Information provided by:
National Cancer Institute (NCI)

Brief Summary:

RATIONALE: Drugs used in chemotherapy, such as S-1, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving S-1 together with bevacizumab may kill more tumor cells.

PURPOSE: This phase II trial is studying how well giving S-1 together with bevacizumab works as third-line therapy in treating patients with colorectal cancer that is recurrent or that cannot be removed by surgery.

Condition or disease Intervention/treatment Phase
Colorectal Cancer Biological: bevacizumab Drug: tegafur-gimeracil-oteracil potassium Phase 2

Detailed Description:


  • To evaluate giving S-1 with bevacizumab to see how well it works as third-line therapy in KRAS-mutation patients with unresectable or recurrent colorectal cancer.

OUTLINE: Patients receive oral S-1 twice daily on days 1-28 and bevacizumab IV on days 1, 15, and 29. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Study of Combination Chemotherapy With S-1 Plus Avastin in Unresectable or Recurrent Colorectal Cancer After Failure of Prior Chemotherapy, Including Irinotecan and Oxaliplatin Regimens.
Study Start Date : July 2009
Estimated Primary Completion Date : June 2010

Resource links provided by the National Library of Medicine

Drug Information available for: Bevacizumab
U.S. FDA Resources

Primary Outcome Measures :
  1. Disease-control rate

Secondary Outcome Measures :
  1. Response rate
  2. Progression-free survival
  3. Overall survival
  4. Safety

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   20 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Histologically confirmed colorectal carcinoma

    • Inoperable, locally advanced, or metastatic disease
    • KRAS-mutated
  • Concurrently receiving treatment containing irinotecan and oxaliplatin regimens for unresectable or recurrent colorectal cancer
  • Measurable disease according to RECIST
  • No moderate or severe ascites or pleural effusion requiring treatment
  • No metastasis to the CNS


  • ECOG performance status 0-2
  • White blood cell count > 3,500/mm³ but < 12,000/mm³
  • Neutrophil count > 1,500/mm³
  • Hemoglobin > 9.0 g/dL
  • Platelet count > 100,000/mm³
  • Total bilirubin < 1.5 mg/dL
  • AST and ALT < 100 U/L (< 200 U/L in patients with liver metastasis)
  • Serum creatinine < 1.2 mg/dL
  • Creatinine clearance ≥ 50 mL/min
  • Urine dipstick for proteinuria < 1+
  • INR < 1.5
  • Not pregnant or nursing
  • Able to take capsules orally
  • No active second cancer
  • No active infections (e.g., patients with pyrexia of ≥ 38°C)
  • No serious complications (e.g., pulmonary fibrosis, interstitial pneumonitis, heart failure, renal failure, hepatic failure, poorly controlled diabetes, or hypertension)
  • No electrocardiographic abnormalities with cardiac disorder that would clinically preclude the execution of the study as judged by the investigator
  • No serious drug hypersensitivity or a history of drug allergy
  • No thrombosis, cerebral infarction, myocardial infarction, or pulmonary embolism
  • No history or evidence of inherited bleeding diathesis or coagulopathy with the risk of bleeding
  • No clinically significant traumatic injury within the past 4 weeks
  • No severe mental disorder


  • See Disease Characteristics
  • Concurrent low-dose aspirin therapy (< 325 mg/day) allowed
  • More than 4 weeks since prior major surgical procedure or open biopsy
  • No prior therapy radiotherapy
  • No prior therapy with S-1
  • No prior chemotherapy include irinotecan and oxaliplatin as first- or second-line treatment.
  • No concurrent continuous treatment with steroids
  • No concurrent treatment with flucytosine

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00974389

Osaka Medical College Recruiting
Takatsuki, Osaka, Japan, 569-8686
Contact: Hiroya Takiuchi, MD, PhD    81-72-683-1221      
Sponsors and Collaborators
Osaka Medical College
Principal Investigator: Hiroya Takiuchi, MD, PhD Osaka Medical College Identifier: NCT00974389     History of Changes
Other Study ID Numbers: OSAKA-TRICC0901
CDR0000649021 ( Registry Identifier: PDQ (Physician Data Query) )
First Posted: September 10, 2009    Key Record Dates
Last Update Posted: August 12, 2013
Last Verified: September 2009

Keywords provided by National Cancer Institute (NCI):
stage III colon cancer
stage III rectal cancer
stage IV colon cancer
stage IV rectal cancer
recurrent colon cancer
recurrent rectal cancer

Additional relevant MeSH terms:
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antineoplastic Agents
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action